Tegoprubart is under clinical development by Eledon Pharmaceuticals and currently in Phase II for Kidney Transplant Rejection. According to GlobalData, Phase II drugs for Kidney Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tegoprubart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tegoprubart overview

Tegoprubart is under development for the treatment of amyotrophic lateral sclerosis (ALS), renal transplantation (kidney transplant rejection), liver transplantation (liver transplant rejection) and autoimmune nephritis including lupus nephritis. The drug candidate is a humanized anti-CD40L monoclonal antibody. It acts by targeting CD40 ligand (CD40L). It is administered through intravenous route.

It was also under development for the treatment of focal segmental glomerulosclerosis (FSGS), Type 1 diabetes, islet transplant rejection and IgA nephropathy (IgAN).

Eledon Pharmaceuticals overview

Eledon Pharmaceuticals is a biotechnology company. Its pipeline products include Tegoprubart, AT-2001. Tegoprubart is for the treatment of kidney transplantation, liver transplantation, xenotransplantation, amyotrophic lateral, sclerosis (ALS), IgA Nephropathy among others. Its pipeline include an androgen receptor degradation agent’s drug discovery program to identify and develop compounds for androgen receptor degradation activity. The company develops treatments for illnesses and disorders of the ears, nose and throat. It has collaborated with pharmaceutical companies to enhance its product candidates. Eledon Pharmaceuticals is headquartered in Irvine, California, the US.

For a complete picture of Tegoprubart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.